Quick Answer
Galmed Pharmaceuticals Ltd. reported Net Income Loss of -$10.31 million for the year ending 2025.
- Galmed Pharmaceuticals Ltd. showed a decrease of -37.1% in Net Income Loss from 2024 to 2025.
- This data is from Galmed Pharmaceuticals Ltd.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 7 years of available data (2019 to 2025), Galmed Pharmaceuticals Ltd.'s Net Income Loss has grown by 49.6%.
- Historical annual values: Fiscal year 2025: -$10.31 million | Fiscal year 2024: -$7.52 million | Fiscal year 2023: -$6.91 million | Fiscal year 2022: -$17.87 million | Fiscal year 2021: -$32.47 million | Fiscal year 2020: -$28.77 million | Fiscal year 2019: -$20.46 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: